Indian concallsQ2 FY27
9 verified earnings call briefs from 9 companies, covering calls held from 28 Sept 2026 to 14 Oct 2026.
How the quarter sounded
- Positive 5 · 56%
- Neutral 4 · 44%
Management's forward-looking tone as judged in each brief, not the share price.5 of 9 calls carried an explicit forward commitment.
Coverage in this quarter
| Sector | Calls | Positive | Neutral | Gave guidance |
|---|---|---|---|---|
| Financial Services | 3 | 1 | 2 | 1 |
| Information Technology | 2 | 1 | 1 | 1 |
| Pharmaceuticals & Healthcare | 2 | 1 | 1 | 1 |
| Automobiles | 1 | 1 | — | 1 |
| Chemicals | 1 | 1 | — | 1 |
TCS reported Q2 FY27 revenue of ₹73,188 crore with 0.5% sequential constant-currency growth, 24% operating margin, US$9.6 billion TCV and annualized AI revenue of $3.1 billion amid selective demand.
- Revenue
- ₹73,188 Cr+1.3% sequentially and 11.2% on a YoY basis
- Constant currency revenue growth
- 0.5% sequentially and 2.8% year-on-year
Subex announced it will report unaudited Q2 FY27 results on November 03, 2026 and hold an earnings call on November 04, 2026, with no financials disclosed in this notice.
HCG has scheduled its Q2 FY27 earnings call for November 6, 2026 to discuss results to be declared on November 5, 2026, with no financials disclosed in this intimation.
This filing only announces the conference call for the quarter ended 30 September 2026 and discloses no financial results.
Q2FY27 was presented as an inflection quarter where 10.4% quarter-on-quarter AUM growth to ₹74,008 crore combined with NIM plus fees expansion to 9.26% and credit cost decline to 2.19% lifted ROA to 2.18%.
- AUM
- ₹74,008 Cr+10.4% QoQ
- Profit after tax
- ₹375 Cr+21.8% QoQ
Ganesh Benzoplast is divesting its JNPA, Goa and Cochin liquid tank farm business for INR1,154 crores to repay debt, return approximately INR200 crores via buyback and special dividend, and expand its chemical and EPC businesses.
- Divestment consideration for JNPA, Goa, Cochin and rail business
- ₹1,154 Cr
- Expected receipt before January of 2027
- approximately ₹500 Cr
This filing only announces the October 15, 2026 board meeting and earnings call for Q2 FY27 with no financial results disclosed yet.
Management said Granules returned to growth in FY26 and is shifting from building manufacturing and R&D capabilities to scaling four growth engines of controlled substances, complex generics with first-to-file opportunities, oncology and peptide CDMO.
- Gross margin
- 65 percentabout 15 percentage points
- EBITDA margin
- 22 percentthree percentage points
Schaeffler India is prioritizing domestic-led growth with 14% to 15% local expansion and about 80% localization, keeping exports at 15% to 20% while investing in automotive, railways and wind capacities.
- Export share of business
- 15% and 20%
- Domestic market growth
- 14% to 15%